share_log

Recursion Pharmaceuticals | 8-K: Current report

SEC ·  Dec 17, 2024 22:08

Summary by Futu AI

Recursion Pharmaceuticals has filed a prospectus supplement on December 17, 2024, to register 3,498,393 shares of its Class A common stock for resale. These shares were issued to Tempus Labs as payment for the 2024 annual license fee under their previously announced Master Agreement.The share offering was conducted under an exemption from registration under the Securities Act of 1933. The registration was made through an automatic "shelf" Registration Statement on Form S-3ASR, which was originally filed with the SEC on May 10, 2022. Legal opinion regarding the legitimacy of the resale shares was provided by Wilson Sonsini Goodrich & Rosati, P.C.
Recursion Pharmaceuticals has filed a prospectus supplement on December 17, 2024, to register 3,498,393 shares of its Class A common stock for resale. These shares were issued to Tempus Labs as payment for the 2024 annual license fee under their previously announced Master Agreement.The share offering was conducted under an exemption from registration under the Securities Act of 1933. The registration was made through an automatic "shelf" Registration Statement on Form S-3ASR, which was originally filed with the SEC on May 10, 2022. Legal opinion regarding the legitimacy of the resale shares was provided by Wilson Sonsini Goodrich & Rosati, P.C.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 661

Recommended